~~<i id='4D52C1A193'><strike id='4D52C1A193'><tt id='4D52C1A193'><pre id='4D52C1A193'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：Wikipedia 2025-10-01 14:18:26 Page View：4591

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 10 states plan to sue EPA over standards for residential wood
Next article： Medicare proposal to cover medical devices draws a mixed reaction

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WASHINGTON--TheSupremeCourtwillreviewarulingstrikingdownadomesticviolencefederalgunban.

Michigan man accused of striking an officer during the US Capitol attack is arrested in Florida

ORLANDO,Fla.--AMichiganmanaccusedofattackingapoliceofficerwithaflagpoleduringtheinsurrectionattheU.S

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

Walmart eyes Medicare Advantage provider ChenMed

Walmartseemspoisedtoincreaseitshealthcarefootprintbybuyingvalue-basedseniorcarecompanyChenMed.JoeRae